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CASE REPORT

An atypical chondroid syringoma with malignant degeneration:
Utility of comparative genomic hybridization in confirming the
diagnosis
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Abstract
Chondroid syringoma (CS) represents the cutaneous counterpart of mixed tumor
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(pleomorphic adenoma) of salivary glands. Definitive diagnosis is made on histopathology and is based on the presence of characteristic epithelial and stromal compo-
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nents. We report a case of an atypical CS arising on the extremity of an elderly male
patient. Histomorphologic features of necrosis and cellular atypia raised suspicion for
malignant degeneration, an exceptionally rare circumstance in this context. To further
support the diagnosis of malignancy, array comparative genomic hybridization was
performed from both low and higher grade areas of the tumor. Both regions demonstrated multiple copy number gains and losses, with additional loss of q7p (TP53), loss
of 19p, and loss of heterozygosity on16q demonstrated in the more atypical foci. To
our knowledge, this is the first case description of malignant degeneration of a CS
with correlative microarray analysis. The findings in this case may prove useful in
confirming the diagnosis in future ambiguous cases.
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I N T RO DU CT I O N

Moreover, the molecular events leading to malignant CS are largely
unknown. Interestingly, there have been cases of CS with a decep-

Chondroid syringoma (CS; also known as cutaneous mixed tumor) is a

tively bland cytological appearance (analogous to so-called benign

benign cutaneous neoplasm of sweat gland origin consisting of both

metastasizing pleomorphic adenoma) that have later proven to behave

epithelial and mesenchymal components.1 It bears morphologic and

in a malignant fashion.7,8 In this report, we describe a case of malig-

genetic resemblance to pleomorphic adenoma, the most common

nant CS arising within an atypical CS in which array comparative

tumor of the salivary glands.2 Features that contribute to a diagnosis

genomic hybridization (aCGH) was found to be especially useful in

of CS include monomorphous epithelial cells arranged in cords and

supporting a diagnosis of malignancy. To our knowledge, this is the

tubules with a peripheral myoepithelial layer, and occurring within a

first report describing cytogenetic alterations in atypical and

3

myxoid or chondroid stroma. Other variably present features include

malignant CS.

foci of squamous differentiation and keratocyst formation, fat metaplasia, and bone formation. Recently it was discovered that some CSs
may harbor fusions in PLAG1, similar to those seen in pleomorphic
2,4

adenoma.
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CASE REPORT

Atypical and malignant forms of CS have been described,

though due to the uncommon nature of these tumors, reliable diag-

An 84-year-old Caucasian male with the past medical history of diabe-

nostic criteria on histomorphology are a matter of debate.5,6

tes and hypertension presented with a slow-growing mass on his right

J Cutan Pathol. 2021;1–6.
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upper extremity near the axilla that had been present for seven years.

bulging into the subcutis. A large proportion of the epithelial cells

On physical examination, a 9 × 7 cm subcutaneous nodule was seen

had associated cytoplasmic vacuolation and clear-cell morphology

at the anteromedial aspect of the right arm. Excision of the mass was

(Figure 4). Focal gland formation and areas of chondroid matrix

recommended given its large size, though the clinical impression was

were appreciated.

initially that of a lipoma.

In the more central and deeper portions of the tumor, areas of

Gross examination revealed a 7.5 × 7 × 4 cm multilobulated

cystic degeneration and necrosis, irregular gland formation, cellular

mass with a thin pseudocapsule. The cut surfaces ranged from pink-

atypia, and mitotic activity were identified (Figure 5). An extended

tan and indurated to red, soft, and hemorrhagic (Figure 1). Micro-

panel of immunohistochemical stains was performed. The cells of

scopically, sections revealed a bulky proliferation of epithelial cells

interest were positive for Sox10, CK7, INI-1, S100, AE1/3 and GATA

arranged in large clusters and solid cords, embedded in a myxoid

(patchy), and were negative for hepatocyte antigen, PAX8, CK20,

and fibrous stroma (Figures 2 and 3). A surrounding rim of fibrosis

CD31, HMB45, Melan A and CD34. Taken together, these findings

was observed, with the tumor cells seen expanding the dermis and

were consistent with a CS with atypical features worrisome for

FIGURE 1

Gross findings: Pseudoencapsulated multilobulated subcutaneous nodule with considerable hemorrhagic necrosis

F I G U R E 2 Variably sized blue
nodules are seen expanding the
dermis and are enveloped in
fibrosis (H&E, ×15)
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F I G U R E 3 The tumor is seen
bulging through the subcutis and
contains numerous cystic foci
along with considerable necrosis
(H&E, ×15)

F I G U R E 4 Numerous
interlacing cords/whorls of
basophilic cuboidal-polygonal
cells are seen embedded in a
myxoid and hyaline stroma (top
panel, H&E, ×100). On higher
power, mucinous foci (bottom left
panel, H&E, ×400) along with
clear-cell cytomorphology is
evident (bottom right panel,
H&E, ×400)

malignant degeneration. As the lesion was dissected out from sur-

A

diagnosis

of

malignancy

was

favored

based

on

rounding normal tissue, margin status could not be determined

histomorphological features alone; namely, the large size, degree of

microscopically.

necrosis, presence of areas with increased mitotic activity, cellular
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F I G U R E 5 Areas of tumor
demonstrating cystic
degeneration and necrosis (top
panel, H&E, ×100). On higher
power, mitotically active
basophilic-pale cuboidal cells are
seen forming irregular glandular
structures and linear cords.
Increased nuclear
hyperchromasia, pleomorphism,
and apoptotic forms are also
evident (lower panel, H&E, ×400)

F I G U R E 6 Microarray plot. Top panel represents lower grade areas of the tumor corresponding to the photomicrographs in Figure 4. Lower
panel represents the more atypical areas of the tumor corresponding to the photomicrographs in Figure 5. Lower panel with additional copy
number changes indicated by the red bar
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atypia, and the identification of highly irregular glandular structures.

Mills determined that CSs are clonal neoplasms consisting of replicating

However, a small degree of doubt was raised based on the lack of dis-

cells with the potential to differentiate toward epithelium or mesen-

cernable host tissue invasion and the possibility that the necrosis was

chyme, which explains the tremendous diversity in histopathologic

procedure-induced/trauma-related. Therefore, aCGH was performed

appearance.15

from two separate regions within the tumor: (a) more conventional-

The malignant variant of CS is extremely infrequent and may arise

appearing low grade area (top plot, Figure 6) more atypical-appearing

from malignant transformation of an otherwise ordinary CS.16 Fea-

higher grade area (lower plot, Figure 6). Multiple copy number gains

tures previously attributed to malignant CS include a greater propen-

and deletions were identified in both sampled areas, consistent with

sity to occur on the extremities, larger size, the presence of cellular

atypical/unstable tumor clones. Specifically gains were seen in

atypia and increased cellularity, increased mitotic rate, invasion of sur-

1p22.2p21.3, 1p21.3p21.1, 1p21.1p13.2, 1q21.1q23.3, 4p16.3q35.2,

rounding tissue, and tumoral necrosis.5,6 Metastasis to regional lymph

16p13.3q22.1, 16q22.1q24.3, 22q11.1q13.33, with losses seen in

nodes, as well as to distant sites such as bone and visceral organs, has

1q32.2q44, 6p25.3q27, 8q12.1q12.2, 12p13.33, 12q12q14.2, and

also been described.5,17 The term “cutaneous mixed tumor with

Xq28 (homozygous loss). The deletions seen at 8q12 and 12q12

atypical features” was previously proposed for tumors with architec-

regions further supported the diagnosis of a myoepithelial neoplasm.9

tural features of malignancy, though without evidence of metasta-

Additionally, the more atypical portion of the tumor demonstrated

sis.5 Wide excision of the primary tumor is generally regarded as the

evidence of clonal evolution with additional loss of 17p13.3p11.2

preferred treatment for the primary tumor, with radiation therapy

(TP53), loss of 19p13.3p13.11, and loss of heterozygosity (LOH) on

and chemotherapy potentially having a role in the setting of metasta-

16q11.2q24.3. Based on this additional information, a low-grade

sis (though the optimal efficacious systemic therapy is unknown

malignant

given the rarity of the tumor overall and lack of randomized con-

CS

was

the

favored

diagnosis.

Correlation

with

intraoperative findings was recommended to ensure that the tumor

trolled trials).18

was adequately excised. A positron emission tomography-computed

Progressive accumulation of genomic changes is a crucial step in

tomography scan failed to reveal any evidence of metastatic disease.

the alteration of normal biological mechanisms and eventual devel-

After discussion of the potential risks/benefits with the patient, the

opment of malignancy within a tumor. aCGH is a molecular cytoge-

decision was made to forgo a wider excision and to proceed with

netic technique used in detecting chromosomal abnormalities and

close clinical surveillance alone. The patient has remained free of

locating regions of genomic imbalances. Results from our aCGH

detectable recurrence for seven months.

assay further confirmed the lineage of the tumor by identifying early
known genetic events. In the context of myoepithelial neoplasms,
such as CS and pleomorphic adenoma, deletions of the 8q21 region
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and the 12q12q14.2 regions are commonly reported findings.9 The

DISCUSSION

8q21 loss results in the loss of the first exon of the PLAG1 gene and
CS is considered a rare tumor of sweat glands, first described by

is most consistent with a PLAG1 gene (nuclear oncoprotein)

Hirsch and Helwig in 1961.3 The reported incidence of CS is 0.01% to

rearrangement with an unknown partner gene resulting in PLAG1

0.098%.10,11Although there is no distinct clinical feature to aid in defi-

overexpression.2,4,19 The loss of 12q12q14.2 results in dysregulation

nite diagnosis, it usually presents as a firm, asymptomatic, skin col-

of the HMGA2 gene, which encodes for a transcriptional gene

ored, slow-growing, solitary dermal, or subcutaneous nodule. The

regulator.20,21

11-13

typical size ranges from 0.5 to 3 cm.

The most common site of

Furthermore, our results show that aCGH may have a role in the

involvement is the head and neck, and it predominantly affects

clinical setting when faced with a CS with atypical features to help

middle-aged men.10

support or refute a diagnosis of malignant degeneration. This may be

Histopathologically, the lesion is characterized by an admixture of

particularly useful when only some, but not all the morphologic fea-

epithelial and mesenchymal elements; hence the term “mixed tumor.”

tures of malignant CS are identified on prepared sections or when

The proposed histopathologic criteria by Hirsch and Helwig included five

there is considerable atypia confined focally within the lesion. In this

features: (a) nests of cuboidal or polygonal cells; (b) intercommunicating

case, the presence of considerable copy number changes (n = 14)

tubuloalveolar structures lined with two or more rows of cuboidal cells;

combined with the morphologic atypia observed and demonstrable

(c) ductal structures composed of one or two rows of cuboidal cells;

clonal evolution with loss of 17p (TP53) and LOH on 16q (likely

(d) occasional keratinous cysts; and (e) a matrix of varying composition.

reflecting loss of another tumor suppressor gene) support a diagnosis

The stroma exhibits varying density and can be chondroid, myxoid,

of malignant transformation. In particular, loss of TP53 is known to be

fibrous, hyaline, or osseous. The ductal and tubuloalveolar structures

associated with disease progression and an adverse prognostic impact

consist of two types of cells: the darker, cuboidal to polyhedral cells lin-

in multiple settings including other cutaneous adnexal neoplasms.22,23

ing the inner layer of these structures exhibit epithelial lineage, whereas

Additional larger studies examining the cytogenetic changes in benign

the light, low-cuboidal cells forming the outer layer of these tubular and

CS, atypical CS, and bona fide malignant CS are needed before firm

ductal structures manifest myoepithelial differentiation. Varela-Duran

conclusions can be drawn regarding the exact number/threshold or

et al proposed the pluripotentiality of the myoepithelial cells, citing their

consistent genetic events that are associated with aggressive behavior

role in the production of the chondroid areas of the tumor.14 Later on,

in this context.
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MATERIALS AND METHODS
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Summary of cytogenetic analysis

Following review by a pathologist, 10 slides were cut at 10 μm thickness
from a representative formalin-fixed and paraffin-embedded (FFPE) tissue
block and tumor was macrodissected using a H&E-stained slide as a guide.
DNA was extracted and purified according to the manufacturer's protocols
(Qiagen QIAmp DNA Mini Kit). Extracted DNA was quantified following
the manufacturer's instructions and diluted to a final concentration of
12 ng/μL with a total of 80 ng utilized. Chromosomal microarray analysis
of tumor samples was performed using the OncoScan FFPE Assay, which
utilizes Molecular Inversion Probe (MIP) technology to obtain accurate
genome-wide copy number and LOH profiles. The assay contains 22 000
probes across the genome and targeted cancer regions, allowing for detection of copy number abnormalities at 50 to 100 kb resolution in 900 cancer genes and at 300 kb resolution in other chromosomal regions. Patient
hybridization results are compared to data derived from over 300 FFPE
samples from unaffected tissues. All data were analyzed and reported using
the February 2019 Genome Reference Consortium Human Build 38 patch
release 13 (GRCh38.p13).

4.2

|

Reportable range

Deletions larger than 1 megabase, duplications larger than 2 megabases, and copy neutral LOH larger than 5 megabases are generally
reported; however, complex genomic alterations may be reported in
aggregate, and well-documented pathogenic constitutional and/or
acquired abnormalities of any size may also be reported. The genome
coordinates described are best estimates and may not represent precise breakpoints, especially for abnormalities detected in a low percentage of cells. The detection threshold for mosaicism is variable,
depending on the size of the segment. Common population number
variants cited in the Database of Genomic Variants are not reported.
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